Tools
Stock profile

Celcuity Inc. (CELC)

CELC · Latest close $55.60 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$55.60
As of Nov 18, 2026
Tracked funds holding
5 of 149
2026 Q2 13F filings
Opened / added
0 / 3
vs previous quarter
Trimmed / exited
3
vs previous quarter

Celcuity Inc. (CELC) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 3 funds adding and 3 funds trimming or exiting versus the previous quarter. Latest close $55.60 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Insider trading · 5% holders · Politician trading · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Perceptive Advisors · Baker Bros. Advisors · Avoro Capital Advisors — 5 tracked funds hold CELC. See all holders.

Insider and Congress activity

No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.

Often held alongside

AVALYN PHARMA INC (AVLN) · Beta Bionics, Inc. (BBNX) · IDEAYA BIOSCIENCES INC (IDYA) · Immatics N.V. (IMTX) · KYMERA THERAPEUTICS INC (KYMR) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Perceptive Advisors5.02%3,197,200ADDED (+2.2%) Q3 filed Nov 16
Baker Bros. Advisors4.15%7,915,792HELD Q3 filed Nov 16
Avoro Capital Advisors3.19%3,400,000ADDED (+0.7%) Q3 filed Nov 16
RTW Investments2.95%3,304,903ADDED (+8.7%) Q3 filed Nov 16
Deerfield Management1.58%1,451,014TRIMMED (-15.3%) Q3 filed Nov 16
Polen Capital Management——EXITED
Avoro Capital Advisors——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -44.5% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

144.982.742024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding279 of 8,857 filers
Long-only filers among them274
Change vs 2026 Q1+8 net · 273 entered · 265 exited
Shares reported, all filers56,798,764
Reported value, all filers$6.0B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryServices-Medical Laboratories (SIC 8071)
Net income · FY2025$-177.0M
Total assets · FY2025$466.6M
Shares outstanding48,931,908
Market cap (at latest close)$2.7B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 5, 2026.

Short interest

Shares short · Oct 15, 202610,252,223
Share of shares outstanding20.95%
Days to cover5.76

Shares short at recent settlements — Jul 31, 2026: 10.3M · Aug 14, 2026: 10.5M · Aug 31, 2026: 10.7M · Sep 15, 2026: 11.4M · Sep 30, 2026: 11.0M · Oct 15, 2026: 10.3M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 5, 2026.

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Jul 16, 2026SCHEDULE 13D/A-34.4% (close Jul 17, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Jul 17, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 11, 2026BANK OF AMERICA CORP /DE/SC 13G3,170,1986.5%Jun 30, 2026SEC filing
Jul 16, 2026Baker Bros. Advisors LPSC 13G4,877,96310.0%Jul 14, 2026SEC filing
Jul 16, 2026Baker Bros. Advisors LPSC 13D/A4,877,96310.0%Jul 14, 2026SEC filing
May 15, 2026RTW Investments, LPSC 13G3,039,6216.3%Mar 31, 2026SEC filing
Mar 24, 2026Baker Bros. Advisors LPSC 13D/A9,582,87420.0%Mar 20, 2026SEC filing
Mar 9, 2026Growth Equity Opportunities 18 VGE, LLCSC 13D/A2,285,5614.9%Mar 5, 2026SEC filing
Feb 17, 2026Perceptive Advisors LLCSC 13G/A3,160,2006.8%Dec 31, 2025SEC filing
Feb 17, 2026Avoro Capital Advisors LLCSC 13G3,111,1116.7%Dec 31, 2025SEC filing
Feb 12, 2026Soleus Private Equity Fund II, L.P.SC 13G/A142,1180.3%Dec 31, 2025SEC filing
Jan 16, 2026Growth Equity Opportunities 18 VGE, LLCSC 13D/A2,910,5616.3%Jan 14, 2026SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Screens & lenses

Red Flags

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

Key figures

· Distress Risk (Altman Z″) — Z″-Score: 0.60 · Working capital / assets: 0.90 · Retained earnings / assets: -0.96 · EBIT / assets: -0.37 · Equity / liabilities: 0.27

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Also held by the tracked funds that hold CELC — ranked by lift, the co-holding pattern described in Methodology: AVALYN PHARMA INC (AVLN) · Beta Bionics, Inc. (BBNX) · IDEAYA BIOSCIENCES INC (IDYA) · Immatics N.V. (IMTX) · KYMERA THERAPEUTICS INC (KYMR) · MADRIGAL PHARMACEUTICALS INC (MDGL) · STOKE THERAPEUTICS INC (STOK) · AVALO THERAPEUTICS INC (AVTX).

Recent 8-K filings

FiledItemsSource
Nov 5, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Oct 2, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Sep 30, 20267.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

AVALYN PHARMA INC (AVLN) · Track Record: how the signals scored · Practice timing on CELC

One email a week: the week’s new filings and research. Subscribe free

← CEG  ·  CELH →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.